Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOOD: Methoxyflurane analgesia in vaso-occlusive crises of sickle cell disease
2024-518043-38-00Phase 3Withdrawn
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of methoxyflurane in sickle cell disease (SCD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Mean pain intensity during first hour. Planned start May 2026; status: withdrawn.
02
Drugs
methoxyflurane
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-518043-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518043-38-00.